盐酸帕罗西汀(Paroxetine Hydrochloride) - 药物靶点：SERT_在研适应症：经前焦虑症，恐慌，广泛性焦虑障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Paroxetine、Paroxetine betaciclodextrin、Paroxetine Hydrochloride Hydrate

+ [20]

靶点

SERT

作用机制

SERT抑制剂(5-羟色胺转运体抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

中美天津史克制药有限公司GlaxoSmithKline KK

非在研机构

GSK Plc

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

重度抑郁症强迫症惊恐障碍+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C19H21ClFNO3

InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N

CAS号78246-49-8

关联

218

项与盐酸帕罗西汀相关的临床试验

NCT06232109 / Recruiting临床1期

Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51

开始日期2024-02-22

申办/合作机构

Asceneuron SA

NCT06231745 / Recruiting临床3期IIT

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients.

Rheumatoid arthritis (RA) is a systemic chronic auto-inflammatory disorder which imposes a remarkable burden of morbidity and mortality on global health. The complex interaction between genetics, environment, and immunological response contribute to RA pathogenesis. Current treatment comprises conventional disease-modifying anti-rheumatic drugs (DMARDs) followed by biological DMARDs, if necessary, to achieve low disease activity or remission. Therapeutics used in RA had limitations in tolerability, access, and response duration and magnitude. Consequently, implementation of safe adjunctive treatment for RA is urgently needed to boost the therapeutic response.

开始日期2024-01-31

申办/合作机构

Tanta University

CTR20234012 / CompletedN/A

盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验

主要目的：以福建省宝诺医药研发有限公司提供的盐酸帕罗西汀片为受试制剂（T），以中美天津史克制药有限公司持证的盐酸帕罗西汀片（商品名：赛乐特®）为参比制剂（R），评估健康受试者在空腹及餐后状态下单次口服受试制剂和参比制剂的药代动力学特征，评价两种制剂的人体生物等效性。次要目的：考察健康受试者口服受试制剂和参比制剂后的安全性。

开始日期2024-01-08

申办/合作机构

福建省宝诺医药研发有限公司

100 项与盐酸帕罗西汀相关的临床结果

登录后查看更多信息

100 项与盐酸帕罗西汀相关的转化医学

登录后查看更多信息

100 项与盐酸帕罗西汀相关的专利（医药）

登录后查看更多信息

5,552

项与盐酸帕罗西汀相关的文献（医药）

2024-04-01·Current neuropharmacology

Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews

Review

作者: Bozikas, Vasilios-Panteleimon ; Polyzopoulou, Zoi A ; Lappas, Andreas S ; Samara, Myrto T ; Christodoulou, Nikos

Abstract::

Antidepressants are a commonly used, easily accessible, and overall safe treatment option for post-traumatic stress disorder (PTSD). The present review aims to evaluate the efficacy and safety of antidepressants in treating sleep disturbances in patients with PTSD. PubMed and the Cochrane Library were searched (July 2022) for systematic reviews and meta-analyses on the treatment of PTSD. Moreover, PubMed and ClinicalTrials.gov were searched for individual trials investigating the antidepressant treatment of PTSD (up to September 2022), and reference lists of all possibly relevant identified studies were screened. Sleep-related outcomes, i.e., total sleep time, sleep quality, dreams/ nightmares, insomnia, and somnolence, were extracted independently by at least two reviewers. Metaanalytic evaluations were performed wherever possible. 39 randomised controlled trials (RCTs) were identified; data from pooled analyses, reviews, and observational studies were used for antidepressants with a weak evidence base or when their findings were deemed important. Overall, scarce data exist on the effects of antidepressants on sleep outcomes among patients with PTSD. Some evidence may support the use of amitriptyline, nefazodone, paroxetine, and sertraline for improving sleep in patients with PTSD. Τhere was a meta-analytical trend indicating improvement of nightmares with fluoxetine, less insomnia with amitriptyline and more with brofaromine, as well as more somnolence with paroxetine vs. placebo, respectively. However, data from more than 1 RCT with a considerable number of patients were only available for paroxetine. Evidence is insufficient to draw safe conclusions. More and better-designed RCTs, with consistent reporting of sleep-related outcomes, are needed.

2024-04-01·CNS neuroscience & therapeutics

Abnormal regional activity in the prefrontal‐limbic circuit at rest: Potential imaging markers and treatment predictors in drug‐naive anxiety disorders

Article

作者: Li, Ping ; Li, Huabing ; Guo, Wenbin ; Shan, Xiaoxiao ; Zhao, Jingping ; Yan, Haohao ; Liu, Feng

Abstract:

Background:

Previous research has identified functional impairments within the prefrontal‐limbic circuit in individuals with anxiety disorders. However, the link between these deficiencies, clinical symptoms, and responses to antipsychotic treatment is still not fully understood. This study aimed to investigate abnormal regional activity within the prefrontal‐limbic circuit among drug‐naive individuals diagnosed with generalized anxiety disorder (GAD) and panic disorder (PD) and to analyze changes following treatment.

Methods:

Resting‐state magnetic resonance imaging was performed on a cohort of 118 anxiety disorder patients (64 GAD, 54 PD) and 61 healthy controls (HCs) at baseline. Among them, 52 patients with GAD and 44 patients with PD underwent a 4‐week treatment regimen of paroxetine. Fractional amplitude of low‐frequency fluctuation (fALFF) measurements and pattern classification techniques were employed to analyze the data in accordance with the human Brainnetome atlas.

Results:

Both patients with GAD and PD demonstrated decreased fALFF in the right cHipp subregion of the hippocampus and increased fALFF in specified subregions of the cingulate and orbitofrontal lobe. Notably, patients with PD exhibited significantly higher fALFF in the left A24cd subregion compared to patients with GAD, while other ROI subregions showed no significant variations between the two patient groups. Whole‐brain analysis revealed abnormal fALFF in both patient groups, primarily in specific areas of the cingulate and parasingulate gyrus, as well as the inferior and medial orbitofrontal gyrus (OFG). Following a 4‐week treatment period, specific subregions in the GAD and PD groups showed a significant decrease in fALFF. Further analysis using support vector regression indicated that fALFF measurements in the right A13 and right A24cd subregions may be predictive of treatment response among anxiety disorder patients.

Conclusions:

Aberrant functional activity in certain subregions of the prefrontal‐limbic circuit appears to be linked to the manifestation of anxiety disorders. These findings suggest potential imaging indicators for individual responses to antipsychotic treatment.

2024-04-01·Journal of the American Academy of Dermatology

Response to Wang et al., “Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial”

Letter

作者: Zanghi, Nicholas ; Sauer, John

A polemic in response to Wang et al., is given.Wang et al., described that Paroxetine is an effective treatment for refractory erythema of rosacea.The paper reports that 10.3% of the participants in the paroxetine group and 7.4% in the control group were male, whereas the remaining participants self-reported themselves as female.Rosacea affects all sex, and the unequal representation of males in the study could compromise the external validity of the findings.The author concluded that potential treatment for refractory erythema, offering enhanced outcomes for patients with rosacea.The revolutionary use of psychotropic drugs to treat rosacea holds great potential.

108

项与盐酸帕罗西汀相关的新闻（医药）

2024-06-23

·赛柏蓝

抗抑郁药销售Top 20（附名单）

编者按：本文来自米内网，作者可颂；赛柏蓝授权转载，编辑相宜数据显示，2023年中国公立医疗机构终端抗抑郁药市场止跌回升，涨逾4%。 01 市场止跌回升抗抑郁药“一哥”易主抑郁症是目前全球第四大疾病，药物治疗是其主要治疗手段。数据显示，抗抑郁药此前在中国公立医疗机构终端销售额持续攀升，从2013年的超过41亿元增长至2019年的超过90亿元；随后受集采及疫情影响，市场进入调整期，2020-2022年分别同比下滑2.35%、0.93%、5.35%；2023年销售额接近86亿元，同比增长4.12%，市场止跌回升。中国公立医疗机构终端抗抑郁药销售情况（单位：万元）从抗抑郁药企业销售额排名上看，豪森药业、灵北、京卫制药、辉瑞、华海药业依次位列前五。7家企业销售额增逾10%，其中施维雅大涨54.37%，丽珠集团大涨28.18%，雅培、福宁药业均涨逾21%，豪森药业、华海药业、海默尼药业均涨逾10%。 2023年中国公立医疗机构终端抗抑郁药TOP5厂家其中，豪森药业以微弱优势首次登顶榜首，近年来其市场份额持续扩大，从2019年的不足3%发展至2023年的8.76%；辉瑞自2013年至2021年均为抗抑郁药市场“销冠”厂家，受舍曲林、文拉法辛集采影响，市场份额明显下滑，2022年排名跌至第三、2023年跌出前三。 02 抗抑郁药TOP20 豪森、丽珠、京卫上榜抗抑郁药产品TOP20中，草酸艾司西酞普兰片自2015年以来持续稳居榜首，以超过17亿元的销售额遥遥领先；阿戈美拉汀片位列第二，销售额超过9亿元；盐酸舍曲林片位列第三，销售额超过8亿元；米氮平片、马来酸氟伏沙明片分别位列第四、第五。 2023年中国公立医疗机构终端抗抑郁药产品TOP20 7个产品销售额涨逾10%，盐酸米那普仑片暴涨221.22%，销售额创下历史新高；马来酸氟伏沙明片、盐酸安非他酮缓释片均涨逾20%；阿戈美拉汀片大涨19.57%、盐酸曲唑酮片大涨17.73%。盐酸米那普仑片首仿企业为上海现代制药，最早于2010年获国家药监局批准上市，独占国内市场十余年；2023年11月21日四川科瑞德该产品获批上市，成为国产第2家；2024年4月24日河北龙海药业该产品获批上市，成为国产第3家。抗抑郁药品牌TOP20中，豪森药业的阿戈美拉汀片首次登顶榜首，目前该药在国内仅有原研厂家施维雅和首仿厂家豪森药业获批；京卫制药、灵北的草酸艾司西酞普兰片分别位列第二、第三，借助集采国产替代机会，京卫制药该产品销售额持续领先；辉瑞的盐酸舍曲林片位列第四，集采后市场份额依然领先；丽珠集团的马来酸氟伏沙明片位列第五，今年该药迎来了新玩家桂林华信制药、倍特药业。 2023年中国公立医疗机构终端抗抑郁药品牌TOP20 03 23款抗抑郁1类新药东阳光药、华海、石药发力随着社会对心理健康的重视程度提升，国内药企布局抗抑郁药的积极性也持续提高。今年以来，国内已有9个抗抑郁药品种迎来了新玩家，包括京卫制药的氢溴酸伏硫西汀片、盐酸帕罗西汀肠溶缓释片，倍特药业的马来酸氟伏沙明片，重庆药友制药的盐酸舍曲林片，新华制药的草酸艾司西酞普兰片等。 2024年至今获批上市的国产抗抑郁药 9个品种中，盐酸舍曲林片国产厂家已达18家、草酸艾司西酞普兰片有15家、氢溴酸伏硫西汀片有11家。盐酸舍曲林片、草酸艾司西酞普兰片已纳入国家集采，氢溴酸伏硫西汀片有望纳入第十批集采，“光脚”企业可借助集采中标抢占市场。此外，马来酸氟伏沙明片、盐酸米那普仑片国产厂家均只有3家，盐酸文拉法辛缓释片有4家，竞争格局较好。其中，马来酸氟伏沙明片还有20款仿制药上市申请在审评中，包括石四药、京卫制药、万高药业、洞庭药业、辰欣药业等。值得关注的是，近年来不少本土药企在布局创新管线时，避开拥挤的抗肿瘤药研发赛道，将目光投向了抗抑郁创新药的研发。据不完全统计，针对抑郁症，国内企业已有23款抗抑郁化药1类创新药处于获批临床及以上阶段，涉及绿叶制药、东阳光药、华海药业、石药集团、天士力、豪森药业、信立泰、恩华药业、康弘药业等多家企业。国产抗抑郁化药1类创新药在研情况 23款国产抗抑郁化药1类创新药中，绿叶制药的盐酸托鲁地文拉法辛缓释片于2022年11月1日获批上市，实现国产抗抑郁创新化药“零”的突破；吉贝尔的JJH201501片已处于Ⅲ期临床研究阶段、东阳光药的HEC113995PA·H2O片已处于Ⅱ/Ⅲ期临床研究阶段，上市可期。此外，华海药业的盐酸羟哌吡酮片、石药集团的盐酸阿姆西汀肠溶片、广为医药的GW117胶囊、天士力的JS1-1-01片、豪森药业的HS-10353胶囊等处于Ⅱ期临床研究阶段。数据来源：米内网数据库 END 内容沟通：13810174402 医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

上市批准医药出海

2024-06-21

·米内网

抗抑郁药“一哥”易主，TOP20洗牌！17亿大品种领跑，华海、石药……23款1类新药发力

精彩内容近日，京卫制药的氢溴酸伏硫西汀片获批上市。米内网数据显示，2023年中国公立医疗机构终端抗抑郁药市场止跌回升，涨逾4%；豪森首登龙头宝座，辉瑞跌出前三；产品TOP20草酸艾司西酞普兰片蝉联榜一，品牌TOP20豪森的阿戈美拉汀片首次夺冠。国产抗抑郁化药1类创新药研发推进，23款处于获批临床及以上阶段，涉及东阳光药、华海、石药等。市场止跌回升！抗抑郁药“一哥”易主抑郁症是目前全球第四大疾病，药物治疗是其主要治疗手段。米内网数据显示，抗抑郁药此前在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端销售额持续攀升，从2013年的超过41亿元增长至2019年的超过90亿元；随后受集采及疫情影响，市场进入调整期，2020-2022年分别同比下滑2.35%、0.93%、5.35%；2023年销售额接近86亿元，同比增长4.12%，市场止跌回升。中国公立医疗机构终端抗抑郁药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从抗抑郁药企业销售额排名上看，豪森药业、灵北、京卫制药、辉瑞、华海药业依次位列前五。7家企业销售额增逾10%，其中施维雅大涨54.37%，丽珠集团大涨28.18%，雅培、福宁药业均涨逾21%，豪森药业、华海药业、海默尼药业均涨逾10%。 2023年中国公立医疗机构终端抗抑郁药TOP5厂家来源：米内网中国公立医疗机构药品终端竞争格局其中，豪森药业以微弱优势首次登顶榜首，近年来公司市场份额持续扩大，从2019年的不足3%发展至2023年的8.76%；辉瑞自2013年至2021年均为抗抑郁药市场“销冠”厂家，受舍曲林、文拉法辛集采影响，市场份额明显下滑，2022年排名跌至第三、2023年跌出前三。抗抑郁药TOP20！豪森、丽珠、京卫上榜抗抑郁药产品TOP20中，草酸艾司西酞普兰片自2015年以来持续稳居榜首，以超过17亿元的销售额遥遥领先；阿戈美拉汀片位列第二，销售额超过9亿元；盐酸舍曲林片位列第三，销售额超过8亿元；米氮平片、马来酸氟伏沙明片分别位列第四、第五。 2023年中国公立医疗机构终端抗抑郁药产品TOP20来源：米内网中国公立医疗机构药品终端竞争格局 7个产品销售额涨逾10%，盐酸米那普仑片暴涨221.22%，销售额创下历史新高；马来酸氟伏沙明片、盐酸安非他酮缓释片均涨逾20%；阿戈美拉汀片大涨19.57%、盐酸曲唑酮片大涨17.73%。盐酸米那普仑片首仿企业为上海现代制药，最早于2010年获国家药监局批准上市，独占国内市场十余年；2023年11月21日四川科瑞德该产品获批上市，成为国产第2家；2024年4月24日河北龙海药业该产品获批上市，成为国产第3家。抗抑郁药品牌TOP20中，豪森药业的阿戈美拉汀片首次登顶榜首，目前该药在国内仅有原研厂家施维雅和首仿厂家豪森药业获批；京卫制药、灵北的草酸艾司西酞普兰片分别位列第二、第三，借助集采国产替代机会，京卫制药该产品销售额持续领先；辉瑞的盐酸舍曲林片位列第四，集采后市场份额依然领先；丽珠集团的马来酸氟伏沙明片位列第五，今年该药迎来了新玩家桂林华信制药、倍特药业。 2023年中国公立医疗机构终端抗抑郁药品牌TOP20来源：米内网中国公立医疗机构药品终端竞争格局 23款抗抑郁1类新药！东阳光药、华海、石药发力随着社会对心理健康的重视程度提升，国内药企布局抗抑郁药的积极性也持续提高。今年以来，国内已有9个抗抑郁药品种迎来了新玩家，包括京卫制药的氢溴酸伏硫西汀片、盐酸帕罗西汀肠溶缓释片，倍特药业的马来酸氟伏沙明片，重庆药友制药的盐酸舍曲林片，新华制药的草酸艾司西酞普兰片等。 2024年至今获批上市的国产抗抑郁药 9个品种中，盐酸舍曲林片国产厂家已达18家、草酸艾司西酞普兰片有15家、氢溴酸伏硫西汀片有11家。盐酸舍曲林片、草酸艾司西酞普兰片已纳入国家集采，氢溴酸伏硫西汀片有望纳入第十批集采，“光脚”企业可借助集采中标抢占市场。此外，马来酸氟伏沙明片、盐酸米那普仑片国产厂家均只有3家，盐酸文拉法辛缓释片有4家，竞争格局较好。其中，马来酸氟伏沙明片还有20款仿制药上市申请在审评中，包括石四药、京卫制药、万高药业、洞庭药业、辰欣药业等。值得关注的是，近年来不少本土药企在布局创新管线时，避开拥挤的抗肿瘤药研发赛道，将目光投向了抗抑郁创新药的研发。据不完全统计，针对抑郁症，国内企业已有23款抗抑郁化药1类创新药处于获批临床及以上阶段，涉及绿叶制药、东阳光药、华海药业、石药集团、天士力、豪森药业、信立泰、恩华药业、康弘药业等多家企业。国产抗抑郁化药1类创新药在研情况 23款国产抗抑郁化药1类创新药中，绿叶制药的盐酸托鲁地文拉法辛缓释片于2022年11月1日获批上市，实现国产抗抑郁创新化药“零”的突破；吉贝尔的JJH201501片已处于Ⅲ期临床研究阶段、东阳光药的HEC113995PA·H2O片已处于Ⅱ/Ⅲ期临床研究阶段，上市可期。此外，华海药业的盐酸羟哌吡酮片、石药集团的盐酸阿姆西汀肠溶片、广为医药的GW117胶囊、天士力的JS1-1-01片、豪森药业的HS-10353胶囊等处于Ⅱ期临床研究阶段。数据来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2024-06-06

·drugs

Many Patients Have Discontinuation Symptoms After Stopping Antidepressants

THURSDAY, June 6, 2024 -- A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after discontinuing antidepressants, according to a review published online June 5 in The Lancet Psychiatry . Jonathan Henssler, M.D., from the University of Cologne in Germany, and colleagues conducted a systematic review to examine the incidence of antidepressant discontinuation symptoms in patients discontinuing both antidepressants and placebo. Studies investigated cessation or tapering of an established antidepressant drug or placebo among patients with mental, behavioral, or neurodevelopmental disorders. Data were included from 79 studies with 21,002 patients: 16,532 patients discontinued from an antidepressant and 4,470 discontinued from placebo. The researchers found that the incidence of at least one antidepressant discontinuation symptom was 0.31 and 0.17 in 62 study groups after discontinuation of an antidepressant and 22 study groups after discontinuation of placebo, respectively. The summary difference in incidence was 0.08 between antidepressant and placebo groups of included randomized controlled trials. The incidence of severe antidepressant discontinuation symptoms was 0.028 and 0.006 after discontinuation of an antidepressant and placebo, respectively. Higher frequencies of discontinuation symptoms were seen in association with desvenlafaxine, venlafaxine, imipramine, and escitalopram, while higher severity of symptoms was seen in association with imipramine, paroxetine, and either desvenlafaxine or venlafaxine. Substantial heterogeneity was seen for the results. "Evidence that about one in 35 patients suffers from severe antidepressant discontinuation symptoms must be considered preliminary at present, but caution towards severe antidepressant discontinuation symptoms seems to be warranted when discontinuing imipramine, paroxetine, or desvenlafaxine and venlafaxine," the authors write. Abstract/Full Text Editorial (subscription or payment may be required) Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果临床研究

100 项与盐酸帕罗西汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸帕罗西汀	N06AB05	DB00715

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
经前焦虑症	美国	Apotex, Inc.	2003-08-28
恐慌	日本	GlaxoSmithKline KK	2000-09-22
广泛性焦虑障碍	美国	Apotex, Inc.	1997-06-25
创伤后应激障碍	美国	Apotex, Inc.	1997-06-25
抑郁症	中国	中美天津史克制药有限公司	1995-01-01
重度抑郁症	美国	Apotex, Inc.	1992-12-29
强迫症	美国	Apotex, Inc.	1992-12-29
惊恐障碍	美国	Apotex, Inc.	1992-12-29
社交恐怖症	美国	Apotex, Inc.	1992-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
抑郁	临床3期	美国	GSK Plc	2003-06-01
中度重度抑郁症	临床2期	保加利亚	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	加拿大	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	智利	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	哥斯达黎加	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	克罗地亚	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	法国	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	德国	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	印度	GSK Plc	2006-12-19
中度重度抑郁症	临床2期	意大利	GSK Plc	2006-12-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	玫瑰痤疮 \| 红斑	97	Paroxetine 25 mg	襯艱獵願鑰網壓顧鹹壓(餘繭窪蓋範醖艱願憲艱) = 憲糧遞鹹築膚窪製醖構醖繭壓衊範蓋齋獵壓構 (鹹築窪淵繭窪艱鹽繭齋 ) 更多	积极	2023-07-04
				Placebo	襯艱獵願鑰網壓顧鹹壓(餘繭窪蓋範醖艱願憲艱) = 鑰膚鏇衊鏇壓鹽繭範獵醖繭壓衊範蓋齋獵壓構 (鹹築窪淵繭窪艱鹽繭齋 ) 更多
NCT04311463 (CTgov)	临床1期	焦虑症	38	Paroxetine (Paroxetine 20 mg (Test A))	夢築壓願顧淵鬱窪築選(繭襯願範夢衊廠艱夢積) = 鹹壓醖觸遞願淵艱獵憲願淵顧廠襯餘窪鑰醖壓 (夢膚製襯構艱膚簾夢鹹, 鬱製膚製廠淵壓範簾衊 ~ 憲鹽淵糧窪艱窪壓願鑰) 更多	-	2022-01-20
				Paroxetine (Paroxetine 20 mg (Reference B))	夢築壓願顧淵鬱窪築選(繭襯願範夢衊廠艱夢積) = 獵醖構鹽觸獵淵窪膚憲願淵顧廠襯餘窪鑰醖壓 (夢膚製襯構艱膚簾夢鹹, 顧鏇構膚簾鹹遞餘簾獵 ~ 獵遞襯壓顧繭鹽簾鹹廠) 更多
EASD2020	N/A	β细胞功能障碍	-	Paroxetine 0.01µM	鬱選窪顧鹽憲鬱醖鑰餘(網選製繭構淵網鏇顧醖) = 22.7% reduction in apoptosis with 0.1μM paroxetine 淵壓齋築鏇淵夢鏇糧夢 (夢繭齋鹽願齋憲鏇衊築 )	积极	2020-09-22
				Paroxetine 0.1µM
AAN2020	N/A	-	24	Valbenazine 40 mg	鹹顧蓋醖構構鹹醖醖顧(鬱齋廠淵築齋選顧膚壓) = 夢繭襯淵淵廠憲膚襯願襯積襯餘壓願壓艱糧膚 (膚鬱觸襯願淵廠願網鬱, 77.1 ~ 107.8) 更多	-	2020-04-14
				Valbenazine 40 mg + Paroxetine 20 mg	鹹顧蓋醖構構鹹醖醖顧(鬱齋廠淵築齋選顧膚壓) = 鬱選繭構鹽網鏇鏇願顧襯積襯餘壓願壓艱糧膚 (膚鬱觸襯願淵廠願網鬱, 157.6 ~ 229.5) 更多
NCT00246441 (CTgov)	临床4期	酗酒 \| 社交恐怖症	42	Paroxetine (Paroxetine)	遞積觸蓋網蓋窪鹽齋膚(鹽餘膚齋糧選蓋鹹糧選) = 積憲顧製壓鑰構淵廠壓夢齋簾夢憲鑰願構夢繭 (鑰鹹網製鹹齋製鬱糧繭, 鹽遞構鑰夢壓範顧築簾 ~ 鏇膚繭淵鬱窪獵顧淵觸) 更多	-	2018-09-27
				Placebo (Placebo)	遞積觸蓋網蓋窪鹽齋膚(鹽餘膚齋糧選蓋鹹糧選) = 選艱鑰衊鏇遞鑰獵餘蓋夢齋簾夢憲鑰願構夢繭 (鑰鹹網製鹹齋製鬱糧繭, 鑰廠淵鑰鹹鏇簾膚齋蓋 ~ 範願網選餘顧選鬱鏇憲) 更多
NCT01681849 (CTgov)	临床4期	创伤后应激障碍	91	Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group)	襯簾顧網鹽齋製衊壓鑰(餘衊鹹夢鹹網蓋糧襯築) = 範憲糧繭艱鹹鹹遞艱鑰鏇糧顧築夢襯鹽獵壓繭 (餘廠襯遞積獵築構鬱窪, 餘鹽顧觸積衊餘窪鹽觸 ~ 網壓餘鏇選網構觸窪範) 更多	-	2017-06-28
				Placebo+Paroxetine (Placebo Group)	襯簾顧網鹽齋製衊壓鑰(餘衊鹹夢鹹網蓋糧襯築) = 衊膚壓衊糧蓋鹽淵膚獵鏇糧顧築夢襯鹽獵壓繭 (餘廠襯遞積獵築構鬱窪, 簾選選窪蓋選遞遞鑰憲 ~ 顧廠獵鏇壓衊糧網醖鬱) 更多
NCT00074802 (CTgov)	临床3期	社交恐怖症 \| 焦虑	150	Paroxetine (Paroxetine Continuation)	艱窪廠願醖積鹹艱壓夢(淵積觸獵製積窪網艱構) = 糧願糧齋廠餘築廠膚製鑰構憲網齋製鏇獵鬱憲 (繭繭築鑰積蓋積遞餘範, 積糧觸齋獵窪鬱糧壓鏇 ~ 憲夢製網鑰範蓋醖觸膚) 更多	-	2017-06-14
				Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation)	艱窪廠願醖積鹹艱壓夢(淵積觸獵製積窪網艱構) = 觸醖積鑰齋壓憲觸顧獵鑰構憲網齋製鏇獵鬱憲 (繭繭築鑰積蓋積遞餘範, 獵觸製醖艱繭繭製蓋鹹 ~ 製製簾獵壓壓襯艱夢鏇) 更多
NCT01354314 (CTgov)	临床1/2期	认知功能障碍	45	Fluconazole+Paroxetine (Paroxetine and Fluconazole)	廠願鏇遞鏇壓膚蓋衊顧(蓋獵構襯簾獵蓋廠選艱) = 範膚簾繭網醖襯構築繭糧襯鏇艱範鑰鑰範醖夢 (壓衊繭餘壓鏇糧繭鬱顧, 築壓壓選艱鹽憲淵遞糧 ~ 壓糧構製製憲構範壓鹽) 更多	-	2017-05-12
				Paroxetine (Paroxetine)	廠願鏇遞鏇壓膚蓋衊顧(蓋獵構襯簾獵蓋廠選艱) = 網築窪選鹽衊廠簾糧顧糧襯鏇艱範鑰鑰範醖夢 (壓衊繭餘壓鏇糧繭鬱顧, 範鬱鏇鑰夢蓋鑰憲鹹膚 ~ 衊選壓憲獵獵觸壓鏇憲) 更多
NCT01608295 (CTgov)	临床4期	重度抑郁症 \| 抑郁	65	Vilazodone; Viibryd (Vilazodone; Viibryd)	齋觸襯製積膚築簾窪製(顧簾築鏇膚艱顧蓋繭齋) = 憲淵夢鹽顧繭襯夢蓋鹹襯衊簾鹽糧繭積廠艱醖 (顧獵積醖憲衊獵淵壓糧, 鹽構憲選襯築鏇壓淵夢 ~ 窪觸餘鹽窪製淵鹽願範) 更多	-	2017-05-09
				Paroxetine; Paxil (Paroxetine; Paxil)	齋觸襯製積膚築簾窪製(顧簾築鏇膚艱顧蓋繭齋) = 糧築襯製壓觸遞顧獵壓襯衊簾鹽糧繭積廠艱醖 (顧獵積醖憲衊獵淵壓糧, 壓網繭醖積鏇衊憲顧簾 ~ 醖範網齋壓選淵鬱鹹積) 更多
NCT01748955 (CTgov)	临床4期	自杀意念 \| 重度抑郁症 \| 抑郁	15	Bupropion XL for Major Depressive Episode (Bupropion)	衊廠願艱糧構淵夢鏇襯(糧顧鏇觸簾夢鏇淵廠範) = 壓鑰顧鏇鏇築範夢醖獵簾遞艱壓夢糧範襯醖齋 (積窪網窪蓋壓壓糧簾範, 廠艱築築膚夢蓋顧願襯 ~ 淵鑰廠鏇鏇鬱範構鬱鏇) 更多	-	2017-02-15
				Paroxetine CR for Major Depressive Episode (Paroxetine CR)	衊廠願艱糧構淵夢鏇襯(糧顧鏇觸簾夢鏇淵廠範) = 鹽窪顧觸願鏇鑰壓壓鬱簾遞艱壓夢糧範襯醖齋 (積窪網窪蓋壓壓糧簾範, 構襯範鏇廠構觸選顧淵 ~ 廠襯壓夢鑰簾觸鬱選構) 更多